We have known that endothelial nitric-oxide synthase (eNOS) and oxidative stress may play a key role in cardiac performance in failing rat hearts. However, the interactions between eNOS or oxidative stress and bradykinin (bK) under treatment of calcium channel blockers (CCbs) remain unknown. To elucidate the mechanism underlying the cardioprotective effect of long-acting dihydropyridine CCbs, we evaluated the effect of benidipine on the bK-eNOS and NaD(P)H oxidase pathway in Dahl salt-sensitive (DS) rats with heart failure.
articles Cardioprotective Effect of Benidipine in CHF and angina pectoris. Previously, we have shown that benidipine stimulates eNOS production in the left ventricle (LV) of renovascular hypertensive rats. 6 Recently, Asanuma et al. 7 demonstrated that benidipine limits infarct size via a BK-and NO-dependent mechanism in the canine heart. However, the cardioprotective effects and mechanisms of long-term treatment with benidipine on cardiac dysfunction and remodeling in heart failure remain unknown. We hypothesized that in the LV of Dahl salt-sensitive (DS) hypertensive rat with heart failure, benidipine (i) may be able to improve the cardiac function and remodeling, (ii) reduces production of LOX-1 by suppressing NAD(P)H oxidase p22phox and p47phox expression, and (iii) stimulates eNOS production associated with BK and oxidative stress.
Methods
All procedures were in accordance with our institutional guidelines for animal research and with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Animal models and experimental designs. Male inbred DS and
Dahl salt-resistant (DR) rats (Eisai, Tokyo, Japan) were weaned and fed a diet containing 0.3% NaCl until the age of 6 weeks. Thereafter, they were fed a diet containing 8% NaCl until the age of 18 weeks. The systolic blood pressure was measured by the tail-cuff method at the start of the 8% NaCl diet and at 1-week intervals thereafter. Transthoracic echocardiography evaluating the LV end-diastolic diameter (LVEDD), and per cent of fractional shortening (%FS) were performed at 18 weeks, as described previously. 1 At the age of 11 weeks, when LV hypertrophy developed, DS rats (n = 48) were randomly divided into five groups: rats treated with vehicle (DSHF-V; n = 8), rats treated with hydralazine (2 mg/kg/day, subpressor dose; DSHF-H; n = 7), rats treated with benidipine (2 mg/kg/day, subpressor dose; Kyowa Hakko Kogyo (Tokyo, Japan); DSHF-B; n = 10), rats treated with benidipine plus FR172357 (FR), BK B2 receptor antagonists (30 mg/kg/ day; Fujisawa Pharmaceutical (Tokyo, Japan); DSHF-B+F; n = 13), and rats treated with FR (30 mg/kg/day; DSHF-F; n = 10) alone. Benidipine was dissolved in peanut oil (10 mg/ ml) and subcutaneously administered every other day for 7 weeks. 6 Hydralazine was given at an average dose of 2 mg/ kg/day by being weekly adjusted to the drinking habits of the animals. The selective nature of FR, as a BK B2 receptor antagonist dissolved in dimethyl sulfoxide, has been demonstrated to be orally active and to have a long duration of action in vivo and optimal selectivity. 8 Our preliminary data suggested that 2 mg/kg/day of benidipine, 2 mg/kg/day of hydralazine, and 30 mg/kg/day of FR would not influence blood pressure in rats (data not shown). Age-matched male DR rats fed the same diet served as a control group (DR-C; n = 10).
LV pressure-volume relation. The chest was opened via a midline sternotomy, and the pericardium was dissected to expose the heart. The LV end-systolic pressure-volume relationship (ESPVR) was modified for the conductance catheter technique as described previously. 9 Quantification of mRNA using reverse transcription polymerase chain reaction. All procedures used for messenger RNA (mRNA) extraction, complementary DNA synthesis, polymerase chain reaction (PCR), and quantification of the PCR product have been described in detail in our previous reports. 4, 10, 11 PCR was done using synthetic oligonucleotide primers as previously reported. 4, 10, 11 The numbers of PCR cycles for the 13 genes examined were as follows: eNOS, 30; inducible NOS (iNOS), 31; NAD(P)H oxidase p22phox, 36; p47phox, 32; LOX-1, 38; superoxide dismutase-1 (SOD-1), 32; vascular cell adhesion molecule-1 (VCAM-1), 32; intercellular cell adhesion molecule-1 (ICAM-1), 28; atrial natriuretic peptide (ANP), 29; β-myosin heavy chain (β-MHC), 26; type I collagen, 27; transforming growth factor-β1 (TGF-β1), 32; GAPDH, 22.
Western blot analysis. eNOS, iNOS, NAD(P)H oxidase p22phox, p47phox, LOX-1, SOD-1, VCAM-1, and ICAM-1 proteins were measured as described previously. [9] [10] [11] Activity of p65NF-κB. The p65 nuclear factor (NF)-κB phosphorylation in the LV was measured as described in detail previously. 10, 11 Determination of NADPH oxidase activity. The NADPH oxidase activity in the LV was assessed by the measurement of superoxide-enhanced lucigenin chemiluminescence as described previously. 10, 11 Histologic examination. Histologic examination was performed as described in detail previously. 1, 6, [9] [10] [11] Statistical analysis. All values are expressed as mean ± s.e.m. Mean values were compared among the six groups by ANOVA and the Bonferroni post hoc test for multiple comparisons. A value of P < 0.05 was considered statistically significant. results Physiologic profiles after a 7-week treatment with benidipine in ds rats DSHF-V rats had markedly higher systolic blood pressure than did DR-C rats. Long-term therapy with hydralazine, benidipine, benidipine plus FR, or FR alone did not significantly affect the systolic blood pressure. Body weight (BW) was significantly lower in DSHF-V, DSHF-F, and DSHF-H than in DR-C rats. Long-term treatment with benidipine or benidipine plus FR therapy in DS rats significantly increased BW. In contrast, DSHF-V, DSHF-F, and DSHF-H rats had a higher LV weight/BW compared with DR-C rats. Long-term treatment with benidipine significantly decreased LV weight/BW. However, long-term treatment with benidipine plus FR significantly increased LV weight/BW when compared with benidipine therapy alone. Heart rate was significantly higher in DSHF-V, DSHF-F, and DSHF-H than in DR-C rats. Long-term treatment articles Cardioprotective Effect of Benidipine in CHF with benidipine or benidipine plus FR therapy significantly decreased the heart rate ( Table 1) . lV ees in esPVr and cardiac function for lVedd and %Fs LV Ees and %FS were significantly lower in DSHF-V, DSHF-F, and DSHF-H rats than in DR-C rats. Long-term treatment with benidipine in DS rats significantly ameliorated Ees and %FS. However, long-term treatment with benidipine plus FR therapy significantly decreased Ees and %FS when compared with benidipine therapy alone. LVEDD was significantly higher in DSHF-V, DSHF-F, and DSHF-H rats than in DR-C rats. Long-term treatment with benidipine significantly decreased LVEDD. However, long-term treatment with benidipine plus FR therapy significantly increased LVEDD when compared with benidipine therapy alone ( Table 1) .
cardiovascular remodeling
The wall-to-lumen ratio and perivascular fibrosis were significantly increased in DSHF-V, DSHF-F, and DSHF-H rats when compared with DR-C. Long-term treatment with benidipine caused significant amelioration of these ratios. However, longterm treatment with benidipine plus FR therapy significantly increased the wall-to-lumen ratio and perivascular fibrosis (Figure 1a -f, Table 1 ).
enos and inos expression
The levels of eNOS mRNA and protein expression in the failing stage were significantly decreased in DSHF-V, DSHF-F, and DSHF-H rats when compared with DR-C rats.
Long-term treatment with benidipine significantly improved eNOS expression levels. However, long-term treatment with benidipine plus FR therapy reduced eNOS expression when compared with benidipine therapy alone (Figure 2a,b) . By Data are expressed as mean ± s.e.m. B, benidipine; BW, body weight; Ees, contractility; F, FR172357; FS, fractional shortening; H, hydralazine; HR, heart rate; LVEDD, left ventricular end-diastolic diameter; LVW, left ventricular weight; SBP, systolic blood pressure. *P < 0.05, **P < 0.01 vs. DR-C; ***P < 0.05, † P < 0.01 vs. no treatment of benidipine group; ‡ P < 0.05, § P < 0.01 vs. DSHF-B. contrast, the levels of iNOS expression were significantly increased in DSHF-V, DSHF-F, and DSHF-H rats when compared with DR-C rats. Long-term treatment with benidipine or beni dipine plus FR therapy significantly decreased iNOS expression levels (Figure 2c,d ).
nad(P)h oxidase p22phox, p47phox expression, and activity, loX-1, and sod-1 expression NAD(P)H oxidase p22phox and p47phox expression and activity and LOX-1 expression were significantly higher in DSHF-V, DSHF-F, and DSHF-H rats than in DR-C rats. Longterm treatment with benidipine significantly decreased the NAD(P)H oxidase subunits expression and activity and LOX-1 expression. However, long-term benidipine plus FR therapy increased these parameters when compared with benidipine therapy alone (Figure 3a -f, Table 1 ). By contrast, SOD-1 expression was significantly decreased in DSHF-V, DSHF-F, and DSHF-H rats when compared with DR-C rats. Longterm treatment with benidipine significantly increased SOD-1 expression. However, long-term treatment with benidipine plus FR therapy reduced SOD-1 expression when compared with benidipine therapy alone (Figure 3g,h ).
VcaM-1 and icaM-1 expression and p65nF-κB phosphorylation
VCAM-1 and ICAM-1 expression and p65NF-κB phosphorylation were significantly increased in DSHF-V, DSHF-F, and DSHF-H when compared with DR-C. Long-term treatment with benidipine reduced the VCAM-1 and ICAM-1 expression and p65NF-κB phosphorylation. However, longterm treatment with benidipine plus FR therapy increased these parameters when compared with benidipine therapy alone (Figure 4a-e) .
anP, β-myosin heavy chain, type i collagen, and tgF-β1 expression
Gene expression of ANP, β-myosin heavy chain, type I collagen, and TGF-β1 was significantly higher in DSHF-V, DSHF-F, and DSHF-H than in DR-C. Long-term treatment with benidipine reduced the expression of ANP, β-myosin heavy chain, type I collagen, and TGF-β1 mRNA. However, long-term treatment with benidipine plus FR therapy increased these parameters when compared with benidipine therapy alone (Figure 5a-d) . articles
Cardioprotective Effect of Benidipine in CHF discussion
In this study, long-acting dihydropyridine CCB benidipine, when administered at a dose which did not reduce blood pressure, ameliorated cardiovascular function, microvascular remodeling and gene expression of growth factors in failing hearts of DS rats. On the other hand, hydralazine at the same dose did not have any effect on cardiovascular functions, suggesting that the cardioprotective effects of benidipine may be independent of antihypertensive effects. This study demonstrated that benidipine (i) may be able to improve cardiac dysfunction and remodeling; (ii) reduces production of LOX-1 by suppressing NAD(P)H oxidase p22phox and p47phox expression, and enhancement of SOD-1; and (iii) stimulates eNOS production associated with BK. Thus, these results suggest that benidipine may be useful as a cardioprotective agent associated with BK-NO dependent pathways and oxidative stress and may serve at least as a potential therapeutic strategy for heart failure. With regard to long-acting CCBs and eNOS, several in vitro and in vivo experimental studies have been reported upon. Felodipine showed a marked upregulation of eNOS expression in cultured endothelial cells. Moreover, nifedipine and diltiazem also upregulated eNOS expression in human coronary artery endothelial cells, but no such effects were observed with verapamil. 12 We also evaluated the effects of long-acting CCBs, benidipine, and amlodipine, on eNOS mRNA expression in rats with hypertension. 6, 13 Recent reports showed that amlodipine releases NO from blood vessels and its mechanism is thought to be similar to that of angiotensin-converting enzyme inhibitors, which implies direct BK formation. 14 This study using BK B2 receptor antagonist FR suggests that benidipine may enhance the increase in BK levels in the failing heart, following cardiac NO activation. Xu et al. 15 reported that amlodipine, but not verapamil or nifedipine, dilated rabbit femoral artery and increased venous NO levels through the BK-dependent pathway, and that amlodipine may activate the BK B2 receptor by enhancing local BK production through angiotensin-converting enzyme inhibition. Moreover, interestingly, benidipine increased NO and BK levels of coronary venous blood and limited infarct size via the BK-NO dependent pathways in canine ischemia/reperfusion hearts. 7 Since benidipine, just like other CCBs such as amlodipine, has been reported to activate kallikrein, which activates BK production in tissues, the increases in NO levels during benidipine treatment are thought to be attributable to BK. 16 Based on these these reports, we suggest that upregulation of eNOS expression via BK modification may play a key role in the cardioprotective effects of benidipine.
The eNOS mRNA and protein levels in the benidipine group are nearly double when compared with DR-C without change in systolic blood pressure. The mechanisms for the potent upregulation of eNOS expression via BK modification are unknown. As mentioned above, there are several reports that benidipine increases in eNOS expression in vivo. 6, 17 In addition, benidipine directly enhanced eNOS protein expression, eNOS enzymatic activity and NO production in human umbilical vein endothelial cells. 18 Since endothelial cells do not express the L-type calcium channel that is the primary target molecule of benidipine, the pleiotropic pharmacological action of benidipine may contribute to the enhancement of eNOS expression. In this study, coadministration of BK B2 receptor Values are means ± s.e.m. n = 3-5 per group. *P < 0.05 vs. Dr-C; † P < 0.05, † † P < 0.01 vs. no treatment of benidipine group; ‡ P < 0.05 vs. DSHF-b. articles
Cardioprotective Effect of Benidipine in CHF
antagonist FR with benidipine inhibited the increase in eNOS expression, indicating that benidipine increased eNOS mRNA through B2 receptor activation. BK causes intracellular calcium increase by binding with B2 receptors in endothelial cells and enhancing NO production through eNOS. 19 The precise mechanism by which benidipine activates the BK B2 receptor remains unclear and would require further research. This study showed that the long-acting CCB, benidipine, significantly suppressed cardiac damage with a significant downregulation of oxidative stress in the heart. Oxidative stress is suggested to play a pivotal role in the pathogenesis of atherosclerosis and heart failure; under oxidative stress there is an increased uptake of oxidized low-density lipoprotein via scavenger receptors. The production of reactive oxygen species by NAD(P)H oxidase may be involved in vascular smooth muscle cell growth. In this study, NAD(P)H oxidase p22phox and p47phox mRNA and protein expression and NAD(P)H oxidase activity were enhanced in the failing hearts of DS rats, and these results are practically identical to those of our previous report. 11 Moreover, LOX-1 has been strongly suggested to play a role in the development of atherosclerosis and is believed to be a key atherogenic component relevant to endothelial injury. 20 Elevated expression of LOX-1 may enhance the attenuating effect of oxidized low-density lipoprotein on the endothelium-dependent vasodilatory response through NO inhibition and play a role in the pathophysiology of hypertension. These findings suggest that the oxidative stress-LOX-1 pathway may play a key role in the involvement of impaired endothelium-dependent vasodilation and the pathogenesis of cardiovascular remodeling in DS rats. Moreover, oxidative stress is a stimulus for inflammation, such as cytokines, adhesion molecules (VCAM-1 and ICAM-1) and iNOS. Reactive oxygen species can activate reactive oxygen species-sensitive transcriptional factors, such as NF-κB and activator protein-1, leading to the recruitment of inflammatory cells and the elaboration of iNOS. Some CCBs decrease oxidative stress and inflammation in atherosclerosis. 21 Yoshii et al. 22 demonstrated that amlodipine inhibited atherosclerotic lesion formation and suppressed oxidative stress (NAD(P)H oxidase p47phox, rac-1 mRNA and superoxide production) and inflammation (VCAM-1, and ICAM-1 mRNA) in ApoEKO mice. Therefore, we provide evidence that cardiac dysfunction and remodeling in failing hearts of DS rats may be partly explained by an enhanced NAD(P)H oxidase-LOX-1 pathway, and that the cardioprotective effect of the long-acting CCB, benidipine, may at least partly be due to the inhibition of oxidative stress and inflammation.
Benidipine has been investigated and found to be effective in decreasing blood pressure values in monotherapy or in combination with other antihypertensive agents. However, because chronic treatment with benidipine reduced blood pressure considerably, it is still unclear whether the beneficial effect of benidipine is due to a direct effect or to reduction of the blood pressure. Therefore, we used a subpressor dose of benidipine to determine whether it has a blood pressure-lowering independent effect in DS rats. Moreover, to evaluate whether benidipine is a special CCB with potency for cardioprotective effects, we examined the effects of a subpressor dose with hydralazine in this study. As a result, it has become clear that the observed beneficial effects of benidipine is due to a direct effect but this is not the case for the blood pressure-lowering effects. Therefore, benidipine may be said to have cardioprotective and blood pressure-lowering independent effects in this study.
Sato et al. 23 demonstrated that the development of a miniaturized conductance catheter has made it possible to measure the in situ LV chamber volume precisely in rats. They also showed that the ESPVR displays contractility-dependent curvilinearity. It was reported that the ESPVR is convex toward the pressure axis under the sympathetic condition or under the condition of a small chamber volume, and that it is linear under the sympathectomized condition or the condition of a relatively large chamber volume. 24 Consequently, the slope of the ESPVR was estimated by linear regression analysis. In this study, the Ees was calculated in the experimental condition where the preload was gradually decreased by occlusion of the inferior vena cava; therefore, the ESPVR shifted downward to the left in our study. By contrast, in previous studies, the Ees was calculated in the experimental condition where the afterload was gradually increased by occlusion of the aorta; therefore, the ESPVR shifted upward to the right. 23, 24 Thus, the slope of the linear regression line may be steeper in our study than in previous studies where the ESPVR was convex toward the pressure axis in vivo. There is a limitation in using ESPVR to evaluate the contractility of the myocardium unit because of its dependence on the chamber size and ventricular mass. However, in order to understand the pathophysiological condition of heart failure, assessment of the contractility of the entire heart may be more important than that of the unit myocardium in vivo.
In conclusion, the findings of this study have demonstrated that the BK B2 receptor antagonist impaired the beneficial cardioprotective effects of long-term treatment with benidipine on cardiac function and cardiovascular remodeling, eNOS production, oxidative stress, and inflammation without affecting the systemic blood pressure in the failing hearts of DS rats. These findings suggest that the cardioprotective mechanism of benidipine may be at least associated with the BK-eNOS and oxidative stress pathway.
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